Proton pump inhibitor use is associated with elevated faecal calprotectin levels. A cross-sectional study on subjects referred for colonoscopy

References

• D'Angelo F, Felley C, Frossard JL. Calprotectin in daily practice: where do we stand in 2017? Digestion. 2017;95:293–301.
   PubMed Web of Science ®Google Scholar
• Caviglia GP, Pantaleoni S, Touscoz GA, et al. Fecal calprotectin is an effective diagnostic tool that differentiates inflammatory from functional intestinal disorders. Scand J Gastroenterol. 2014;49:1419–1424.
   PubMed Web of Science ®Google Scholar
• Kalantari H, Taheri A, Yaran M. Fecal calprotectin is a useful marker to diagnose ulcerative colitis from irritable bowel syndrome. Adv Biomed Res. 2015;4:85.
   PubMedGoogle Scholar
• Kawashima K, Ishihara S, Yuki T. Fecal calprotectin predicts relapse and histological mucosal healing in ulcerative colitis. BMC Gastroenterol. 2016;16:47.
   PubMed Web of Science ®Google Scholar
• Theede K, Holck S, Ibsen P, et al. Fecal calprotectin predicts relapse and histological mucosal healing in ulcerative colitis. Inflamm Bowel Dis. 2016;22:1042–1048.
   PubMed Web of Science ®Google Scholar
• Walsham NE, Sherwood RA. Fecal calprotectin in inflammatory bowel disease. Clin Exp Gastroenterol. 2016;9:21–29.
   PubMed Web of Science ®Google Scholar
• Yamaguchi S, Takeuchi Y, Arai K, et al. Fecal calprotectin is a clinically relevant biomarker of mucosal healing in patients with quiescent ulcerative colitis. J Gastroenterol Hepatol. 2016;31:93–98.
   PubMed Web of Science ®Google Scholar
• Poullis A, Foster R, Shetty A, et al. Bowel inflammation as measured by fecal calprotectin: a link between lifestyle factors and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev. 2004;13:279–284.
   PubMed Web of Science ®Google Scholar
• Nielsen HL, Engberg J, Ejlertsen T, et al. Evaluation of fecal calprotectin in Campylobacter concisus and Campylobacter jejuni/coli gastroenteritis. Scand J Gastroenterol. 2013;48:633–635.
   PubMed Web of Science ®Google Scholar
• Kim J, Kim H, Oh HJ, et al. Fecal calprotectin level reflects the severity of Clostridium difficile infection. Ann Lab Med. 2017;37:53–57.
   PubMed Web of Science ®Google Scholar
• Tursi A. Biomarkers in diverticular diseases of the colon. Dig Dis. 2012;30:12–18.
   PubMed Web of Science ®Google Scholar
• Wildt S, Nordgaard-Lassen I, Bendtsen F, et al. Metabolic and inflammatory faecal markers in collagenous colitis. Eur J Gastroenterol Hepatol. 2007;19:567–574.
   PubMed Web of Science ®Google Scholar
• Matzkies FG, Targan SR, Berel D, et al. Markers of intestinal inflammation in patients with ankylosing spondylitis: a pilot study. Scand J Gastroenterol. 2012;47:435–444.
   PubMed Web of Science ®Google Scholar
• Olafsdottir I, Nemeth A, Lörinc E, et al. Value of fecal calprotectin as a biomarker for juvenile polyps in children investigated with colonoscopy. J Pediatr Gastroenterol Nutr. 2016;62:43–46.
   PubMed Web of Science ®Google Scholar
• Lehmann FS, Trapani F, Fueglistaler I, et al. Clinical and histopathological correlations of fecal calprotectin release in colorectal carcinoma. Wjg. 2014;200:4994–4999.
   Web of Science ®Google Scholar
• Pezzilli R, Barassi A, Morselli Labate AM, et al. Fecal calprotectin levels in patients with colonic polyposis. Dig Dis Sci. 2008;53:47–51.
   PubMed Web of Science ®Google Scholar
• Tibble J, Sigthorsson G, Foster R, et al. Faecal calprotectin and faecal occult blood tests in the diagnosis of colorectal carcinoma and adenoma. Gut. 2001;49:402–408.
   PubMed Web of Science ®Google Scholar
• Li F, Ma J, Geng S, et al. Fecal calprotectin concentrations in healthy children aged 1-18 months. PLoS One. 2015;10:e0119574.
   PubMed Web of Science ®Google Scholar
• Tibble JA, Sigthorsson G, Foster R, et al. High prevalence of NSAID enteropathy as shown by a simple faecal test. Gut. 1999;45:362–366.
   PubMed Web of Science ®Google Scholar
• Meling TR, Aabakken L, Røseth A, et al. Faecal calprotectin shedding after short-term treatment with non-steroidal anti-inflammatory drugs. Scand J Gastroenterol. 1996;31:339–344.
   PubMed Web of Science ®Google Scholar
• Maiden L, Thjodleifsson B, Theodors A, et al. A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy. Gastroenterology. 2005;128:1172–1178.
   PubMed Web of Science ®Google Scholar
• Rendek Z, Falk M, Grodzinsky E, et al. Effect of oral diclofenac intake on faecal calprotectin. Scand J Gastroenterol. 2016; 51:28–32.
   PubMed Web of Science ®Google Scholar
• Smecuol E, Pinto Sanchez MI, Suarez A, et al. Low-dose aspirin affects the small bowel mucosa: results of a pilot study with a multidimensional assessment. Clin Gastroenterol Hepatol. 2009;7:524–529.
   PubMed Web of Science ®Google Scholar
• Shiotani A, Kamada T, Haruma K. Low-dose aspirin-induced gastrointestinal diseases: past, present, and future. J Gastroenterol. 2008;43:581–588.
   PubMed Web of Science ®Google Scholar
• Montalto M, Curigliano V, Santoro L, et al. Prophylactic aspirin therapy does not increase faecal calprotectin concentrations. Eur J Gastroenterol Hepatol. 2006;18:965–967.
   PubMed Web of Science ®Google Scholar
• Eklöf V, Löfgren-Burström A, Zingmark C, et al. Cancer-associated fecal microbial markers in colorectal cancer detection. Int J Cancer. 2017;15:141.
   Google Scholar
• Dimenäs E, Glise H, Hallerbäck B, et al. Quality of life in patients with upper gastrointestinal symptoms. An improved evaluation of treatment regimens? Scand J Gastroenterol. 1993;28:681–687.
   PubMed Web of Science ®Google Scholar
• Wiklund IK, Fullerton S, Hawkey CJ, et al. An irritable bowel syndrome-specific symptom questionnaire: development and validation. Scand J Gastroenterol. 2003;38:947–954.
   PubMed Web of Science ®Google Scholar
• Shin SJ, Noh CK, Lim SG, et al. Non-steroidal anti-inflammatory drug-induced enteropathy. Intest Res. 2017;15:446–455.
   PubMed Web of Science ®Google Scholar
• Moore RA, Derry S, McQuay HJ. Faecal blood loss with aspirin, nonsteroidal anti-inflammatory drugs and cyclo-oxygenase-2 selective inhibitors: systematic review of randomized trials using autologous chromium-labelled erythrocytes. Arthritis Res Ther. 2008;10:R7.
   PubMed Web of Science ®Google Scholar
• Poullis A, Foster R, Mendall MA, et al. Proton pump inhibitors are associated with elevation of faecal calprotectin and may affect specificity. Eur J Gastroenterol Hepatol. 2003;15:573–574.
   PubMed Web of Science ®Google Scholar
• Lapenna D, de Gioia S, Ciofani G, et al. Antioxidant properties of omeprazole. FEBS Lett. 1996;382:189–192.
   PubMed Web of Science ®Google Scholar
• Biswas K, Bandyopadhyay U, Chattopadhyay I, et al. A novel antioxidant and antiapoptotic role of omeprazole to block gastric ulcer through scavenging of hydroxyl radical. J Biol Chem. 2003;278:10993–11001.
   PubMed Web of Science ®Google Scholar
• Suzuki M, Nakamura M, Mori M, et al. Lansoprazole inhibits oxygen-derived free radical production from neutrophils activated by Helicobacter pylori. J Clin Gastroenterol. 1995;20:Suppl 2:S93–S96.
   PubMed Web of Science ®Google Scholar
• Handa O, Yoshida N, Fujita N, et al. Molecular mechanisms involved in anti-inflammatory effects of proton pump inhibitors. Inflamm Res. 2006;55:476–480.
   PubMed Web of Science ®Google Scholar
• Kedika RR, Souza RF, Spechler SJ. Potential anti-inflammatory effects of proton pump inhibitors: a review and discussion of the clinical implications. Dig Dis Sci. 2009;54:2312–2317.
   PubMed Web of Science ®Google Scholar
• Kuroda M, Yoshida N, Ichikawa H, et al. Lansoprazole, a proton pump inhibitor, reduces the severity of indomethacin-induced rat enteritis. Int J Mol Med. 2006;17:89–93.
   PubMed Web of Science ®Google Scholar
• Ichikawa H, Yoshida N, Takagi T, et al. Lansoprazole ameliorates intestinal mucosal damage induced by ischemia-reperfusion in rats. Wjg. 2004;10:2814–2817.
   PubMed Web of Science ®Google Scholar
• Vesper BJ, Jawdi A, Altman KW, et al. The effect of proton pump inhibitors on the human microbiota. Curr Drug Metab. 2009;10:84–89.
   PubMed Web of Science ®Google Scholar
• Jackson MA, Goodrich JK, Maxan ME, et al. Proton pump inhibitors alter the composition of the gut microbiota. Gut. 2016;65:749–756.
   PubMed Web of Science ®Google Scholar
• Castellani C, Singer G, Kashofer K, et al. The influence of proton pump inhibitors on the fecal microbiome of infants with gastroesophageal reflux-A prospective longitudinal interventional study. Front Cell Infect Microbiol. 2017;7:444.
   PubMed Web of Science ®Google Scholar
• Andréasson K, Alrawi Z, Persson A, et al. Intestinal dysbiosis is common in systemic sclerosis and associated with gastrointestinal and extraintestinal features of disease. Arthritis Res Ther. 2016;18:278.
   PubMed Web of Science ®Google Scholar
• Hassing RJ, Verbon A, de Visser H, et al. Proton pump inhibitors and gastroenteritis. Eur J Epidemiol. 2016;31:1057–1063.
   PubMed Web of Science ®Google Scholar
• Yousefi R, Imani M, Ardestani SK, et al. Human calprotectin: effect of calcium and zinc on its secondary and tertiary structures, and role of pH in its thermal stability. Acta Biochim Biophys Sinica. 2007;39:795–802.
   PubMed Web of Science ®Google Scholar
• Montalto M, Gallo A, Ianiro G, et al. Can chronic gastritis cause an increase in fecal calprotectin concentrations? World J Gastroenterol. 2010;16:3406–3410.
   PubMed Web of Science ®Google Scholar